KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings

Jennifer Webster, Tia L. Kauffman, Heather Spencer Feigelson, Pamala A. Pawloski, Adedayo A. Onitilo, Arnold L. Potosky, Deanna Cross, Paul R. Meier, Anousheh S. Mirabedi, Thomas Delate, Yihe Daida, Andrew E. Williams, Gwen L. Alexander, Catherine A. McCarty, Stacey Honda, Lawrence H. Kushi, Katrina A.B. Goddard

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Background: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to EGF receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake and utilization of KRAS testing. Methods: We included 1,188 patients with mCRCs diagnosed from 2004 to 2009, from seven integrated health care delivery systems with a combined membership of 5.5 million. We used electronic medical records and targeted manual chart review to capture the complexity and breadth of real-world clinical oncology care. Results: Overall, 428 patients (36%) received KRAS testing during their clinical care, and 266 (22%) were treated with EGFR inhibitors. Age at diagnosis (P = 0.0034), comorbid conditions (P = 0.0316), and survival time from diagnosis (P < 0.0001) influence KRAS testing and EGFR inhibitor prescribing. The proportion who received KRAS testing increased from 7% to 97% for those treated in 2006 and 2010, respectively, and 83% of all treated patients had a KRAS wild-type genotype. Most patients with a KRAS mutation (86%) were not treated with EGFR inhibitors. The interval between mCRC diagnosis and receipt of KRAS testing decreased from 26 months (2006) to 10 months (2009). Conclusions: These findings show rapid uptake and incorporation of this predictive biomarker into clinical oncology care. Impact: In this delivery setting, KRAS testing is widely used to guide treatment decisions with EGFR inhibitors in patients with mCRCs. An important future research goal is to evaluate utilization of KRAS testing in other delivery settings in the United States.

Original languageEnglish
Pages (from-to)91-101
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Issue number1
StatePublished - Jan 2013


Dive into the research topics of 'KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings'. Together they form a unique fingerprint.

Cite this